AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Kelly Maloney, MD
Study ID
Protocol Number: 17-1086
More information available at ClinicalTrials.gov: NCT02981628
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers